Home » Newsletters » BioWorld Science

BioWorld Science

July 13, 2020

View Archived Issues

ADAM9 expression correlates with poor survival in TNBC

Discovery of novel BET protein degraders as oncolytic drug candidates

Crosstalk between sex, stress hormones affects immunity

Astrocytes, endocannabinoids, metabolism cooperate to affect behavior

Liver-specific silencing of MCJ reduces steatosis, inflammation and fibrosis in NASH mouse models

Roche synthesizes new imidazopyrazine antibacterials

Humanwell Healthcare, Hubei Bio-Pharmaceutical patent PDE4 inhibitors

Phase II study of CS-02 meets primary endpoint

New SMARCA2 inhibitors identified at Bayer

Imperial Innovations Group presents N-myristoyltransferase inhibitors

Svenox Pharmaceuticals presents new antitubercular compounds

Aptahem and University Health Network collaborate to develop Apta-1 for treatment of COVID-19

First-in-human study of INV-1120

Aligos Therapeutics presents preclinical data on ALG-031048

NBE-Therapeutics initiates phase I/II study of NBE-002

Enrollment ongoing in phase I study of KBL-693

Celldex Therapeutics starts enrollment in phase I study of CDX-527

BRAF inhibitor ABM-1310 displays potent efficacy in xenograft cancer models

Oragenics advances TerraCoV2, ends development of AG-013 for oral mucositis

Alzumab approved in India for emergency use to treat CRS in patients with COVID-19-related ARDS

Australia's TGA grants provisional approval to remdesivir

Beta Pharma begins phase I/II study of BPI-1178 in advanced solid tumors and breast cancer

Mutation drives checkpoint resistance in gastric cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 26, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 23, 2026.
Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease
BioWorld Science
Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...
Muted and missing M&As: JPM deals absent in 2026
BioWorld
For years, the J.P. Morgan Healthcare Conference (JPM) kicked off with splashy headlines of major M&A activity among biopharma companies, but in 2026, the hype...
Sumitomo’s DSP-3456 exerts antidepressant-like effects
BioWorld Science
About one-third of patients with major depressive disorder (MDD) are treatment resistant. Ketamine is very effective in treatment-resistant depression, but it is...